Lillian L Siu, MD, FRCPC

Dr. Siu is a senior medical oncologist at the Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at the Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026).  She is also the Clinical Lead for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She also served as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016). She currently serves on the AACR Board of Directors for a three-year term (2017-2020).

Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies.  She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine.

Internationally, Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010.  Locally, she was awarded the University of Toronto Department of Medicine Eaton Scholar Researcher in 2016.  She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10. She was Chairperson of the AACR Education Committee, Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting and Co-Chairperson for the Clinical Trials Committee 2015-2017. Dr. Siu has published over 280 peer-reviewed manuscripts, and she is currently a scientific editor for Cancer Discovery and is on the editorial board for JAMA Oncology.

Developmental Therapeutics and Phase I Clinical Trials of Novel Agents

Dr. Siu's major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute, which aims to expedite the access and evaluation of novel anti-cancer agents.

Related Links

Ann Oncol. 2018 Sep 10;:
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G, task force on Methodology for the Development of Innovative Cancer Therapies
BMC Med Genomics. 2018 Aug 09;11(1):65
Stjepanovic N, Stockley TL, Bedard PL, McCuaig JM, Aronson M, Holter S, Semotiuk K, Leighl NB, Jang R, Krzyzanowska MK, Oza AM, Gupta A, Elser C, Ahmed L, Wang L, Kamel-Reid S, Siu LL, Kim RH
Clin Med Insights Oncol. 2018;12:1179554918779581
Malone E, Siu LL
Int J Radiat Oncol Biol Phys. 2018 May 02;:
Ng WT, Tung SY, Lee V, Ngan RKC, Choi HCW, Chan LLK, Leung TW, Siu LL, Lu TX, Tan T, Tan EH, Sze HCK, Ng AWY, Yiu HHY, O'Sullivan B, Chappell R, Lee AWM
Oncotarget. 2018 Apr 27;9(32):22559-22570
Korpanty GJ, Kamel-Reid S, Pintilie M, Hwang DM, Zer A, Liu G, Leighl NB, Feld R, Siu LL, Bedard PL, Tsao MS, Shepherd FA
J Clin Oncol. 2018 May 07;:JCO2018782292
Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C
Head Neck. 2018 Apr 17;:
Bernstein LJ, Pond GR, Gan HK, Tirona K, Chan KK, Hope A, Kim J, Chen EX, Siu LL, Razak ARA
Eur J Cancer. 2018 Apr 06;95:38-51
Iafolla MAJ, Selby H, Warner K, Ohashi PS, Haibe-Kains B, Siu LL
Invest New Drugs. 2018 Apr 03;:
Aghajanian C, Bell-McGuinn KM, Burris HA, Siu LL, Stayner LA, Wheler JJ, Hong DS, Kurkjian C, Pant S, Santiago-Walker A, Gauvin JL, Antal JM, Opalinska JB, Morris SR, Infante JR

Pages


 

Professor of Medicine, University of Toronto
Staff Physician, Division of Medical Oncology and Hematology, Princess Margaret Hospital
Director, Phase I Program and Co-Director, Robert and Maggie Bras and Family Drug Development Program, Princess Margaret Hospital